After four years as CEO, Claus Egstrand is leaving his position at Enzymatica. In his final quarterly report, he reflects on the company’s development and the journey that has taken ColdZyme from scientific validation to commercial strength. BioStock contacted Egstrand to get his thoughts.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/enzymaticas-vd-lamnar-efter-fyra-ar-summerar-en-resa-fran-vetenskap-till-kommersialisering/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se